International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 08 August 2023

Page No: 1619-1622

DOI: https://doi.org/10.47191/ijmscrs/v3-i8-33, Impact Factor: 6.597

Vitiligo: A Comprehensive Review of the Etiology, Pathogenesis and Therapeutic Approaches to a Complex Dermatological Disease of Cutaneous Depigmentation

Nataly Paola Rentería Vázquez[1], Susana González Hernández[2], Brisa Arlin Gómez Arteaga[3], Keren Vazquez Ballesteros[4], Irisdey Espinoza Urzua[5]

[1]Hospital General Regional #1 Instituto Mexicano del Seguro Social, Santiago de Querétaro, Querétaro, México

[2]Hospital General Dr. Dario Fernandez Fierro. Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Ciudad de México, México.

[3]Hospital Regional del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado de León. León, Guanajuato.

[4]Escuela Superior de Medicina, Instituto Politécnico Nacional. México.

[5]Universidad Nacional Autónoma de Mexico, Ciudad de México, México

ABSTRACT

Vitiligo, an enigmatic and complex skin disease, is notable for the appearance of depigmented patches that arise due to the selective and progressive loss of melanocytes, the cells responsible for melanin production. This autoimmune pathology affects individuals of both genders and has been the subject of historical interest due to its unusual clinical presentation and its impact on patients' quality of life. The etiology of vitiligo is multifactorial, involving a combination of genetic, environmental and autoimmune factors leading to melanocyte destruction.

Although diagnosis is usually based on visual examination of the skin lesions, additional tests may be required to rule out other conditions with similar features. Although a definitive cure has not yet been found, a variety of therapeutic approaches, including topical treatments, phototherapy, systemic therapy and surgical options, are available to attempt to repigment affected areas and improve patients' quality of life. Continued research and a deeper understanding of the pathogenesis of vitiligo are essential to address this disease more effectively and provide more successful therapeutic solutions.

KEYWORDS: Vitiligo, Cutaneous depigmentation, Melanocytes, Autoimmunity, Therapeutic treatment.

ARTICLE DETAILS

Published On:
14 August 2023

Available on:
https://ijmscr.org/

INTRODUCTION

Vitiligo is an enigmatic and complex skin disease characterized by the appearance of depigmented skin patches resulting from a progressive and selective loss of melanocytes, the cells responsible for producing melanin, the pigment responsible for skin, hair and eye coloration. This pathology, which affects both men and women, is considered an autoimmune disease, where the individual's immune system mistakenly att

acks its own melanocytes.1

The etiology of vitiligo still remains a challenge to the scientific community, although a combination of genetic, environmental and autoimmune factors have been proposed as possible contributors to its development. Affected areas of the skin present with a noticeable color contrast in relation to the surrounding skin, which can be a cause of aesthetic and psychosocial concern for patients.1

Throughout history, vitiligo has been the subject of interest and mystery due to its distinctive visual appearance and its impact on the quality of life of those who suffer from it. While this condition does not pose a direct threat to physical health, it can have significant emotional consequences, such as anxiety, depression and low self-esteem, due to the social stigmas associated with pigmentation differences.1

EPIDEMIOLOGY

Vitiligo, a complex dermatologic disease of cutaneous depigmentation, has a diverse and widely distributed epidemiology in the world population. This condition is characterized by a global prevalence that varies significantly

according to geographic regions, ethnic groups and demographic characteristics. Although it is not a rare disease, its frequency is heterogeneous and can vary from areas with a low incidence to regions where its prevalence reaches higher figures.1,2

Epidemiological studies have shown that vitiligo affects both genders equally, with no specific sexual predilection. The onset of the disease usually occurs at an early age, with a peak onset in the second and third decade of life, although it can also develop in later stages. Skin involvement may extend over different skin areas, and lesions are classified into different subtypes, such as segmental and nonsegmental vitiligo, which may differ in their epidemiological behavior.2

Vitiligo does not show a uniform distribution in terms of geography, and variations in incidence have been identified according to latitude and altitude. It has been observed that populations living in regions closer to the equator, where solar exposure is higher, have a lower prevalence of vitiligo compared to those living in areas with higher latitudes. In addition, it has been suggested that the incidence of vitiligo may be associated with environmental and climatic factors, such as ultraviolet radiation, exposure to chemicals and certain viral infections.2,3

With regard to genetic predisposition, it has been established that there is a hereditary component to the etiology of vitiligo, with a higher risk of developing the disease in individuals with a family history of affected individuals. Familial aggregation studies have supported this association, suggesting that genetic factors play an important role in susceptibility to this pathology.2,3

The epidemiology of vitiligo shows a diverse global distribution, with differences in prevalence according to geographic, demographic, ethnic and genetic factors. Although it affects both sexes equally, its onset occurs mainly at early ages and its incidence can vary significantly in different regions of the world. A thorough understanding of the epidemiology of this disease is crucial for the planning and implementation of public health strategies, as well as for the development of more effective therapeutic approaches in the management of vitiligo.4

CLINIC

Vitiligo, a complex dermatological entity, is clinically manifested by the appearance of depigmented skin lesions resulting from the loss of melanin in specific areas of the skin. These clinical manifestations are characterized by their typical appearance of well-demarcated white macules, which may vary in size and shape, and may affect various anatomical locations. The distribution of the lesions in vitiligo can present variable patterns, such as symmetry, asymmetry or segmentation, the latter being a distinctive feature in segmental vitiligo.5

The disease can present in different clinical forms, which are mainly classified into two main subtypes: nonsegmental vitiligo and segmental vitiligo. In non-segmental vitiligo, also known as vitiligo vulgaris, the lesions tend to be bilateral and symmetrical, similarly affecting both halves of the body, whereas in segmental vitiligo, the depigmented macules are distributed following a dermatomal pattern, i.e. along a specific nerve pathway.5

The clinical course of vitiligo can be highly variable, with an evolution that can be slow and progressive or, in some cases, present a spontaneous arrest of cutaneous depigmentation. Affected areas of the skin may be highly sensitive to sun exposure, which can result in sunburn and increase contrasting hypopigmentation.5

In addition to its cutaneous manifestations, vitiligo can have significant psychosocial consequences in affected patients. The presence of depigmented macules, especially in visible areas such as the face, hands or neck, can have a negative emotional impact, leading to problems of self-esteem, anxiety and depression.5,6

The clinical presentation of vitiligo is characterized by the appearance of well-demarcated depigmented macules on the skin, with a variety of shapes and distributions. Identification of the different clinical subtypes, as well as consideration of the emotional and social implications, are fundamental to a comprehensive approach to the management of this complex dermatologic disease.6,7

DIAGNOSTIC

The diagnosis of vitiligo involves a thorough and meticulous medical approach, considering both the clinical findings and the patient's clinical history. Since this complex dermatologic entity may present with clinical features similar to other skin depigmenting diseases, a thorough differential evaluation is essential to rule out other conditions.8

Anamnesis plays a crucial role in the diagnostic process, where detailed information is collected on the onset, evolution and pattern of appearance of the skin lesions. It is important to obtain a family history of vitiligo or other autoimmune diseases, as well as to identify possible triggering factors, such as emotional or traumatic events, excessive sun exposure or previous infectious diseases.9,10

Thorough clinical examination is essential to identify the distinctive features of vitiligo. Well-demarcated, depigmented macules with regular borders and absence of desquamation may present a variety of shapes and sizes, and their distribution may be symmetrical or asymmetrical, depending on the subtype of vitiligo. In addition, look for lesions that follow dermatomal patterns in segmental vitiligo.11

Occasionally, to confirm the diagnosis and rule out other similar diseases, additional tests may be necessary. Wood's lamp, an ultraviolet light source, can be used to identify hypopigmented lesions, as they may glow bluish under this special light. In addition, skin biopsies can be performed to

histologically examine the lesions and rule out other depigmenting conditions.11

Evaluation of the patient's autoimmune status may also be relevant, as vitiligo is often associated with other autoimmune diseases, such as hypothyroidism and Addison's disease. Therefore, laboratory tests can be performed to analyze thyroid hormone levels and adrenal function.11

It is important to note that the diagnosis of vitiligo can be challenging due to its broad clinical spectrum and the possibility of confusion with other conditions. Therefore, a multidisciplinary approach involving dermatologists, autoimmune disease specialists and other healthcare professionals may be necessary to reach an accurate diagnosis.11

In summary, the diagnosis of vitiligo is based on a detailed clinical evaluation, supported by the patient's medical history and, in some cases, by complementary tests. Accurate identification of the distinguishing features of vitiligo and exclusion of other skin depigmenting diseases are essential for an accurate diagnosis and proper management of this complex dermatologic disease.11

TREATMENT

The therapeutic management of vitiligo is a challenge for healthcare professionals due to the complex nature of this dermatologic disease. The therapeutic approach focuses on attempting to repigment affected areas, improve cosmetic appearance and address the associated psychosocial implications. However, it is essential to keep in mind that vitiligo is a chronic condition and, in many cases, treatment may not be curative, but rather palliative.12

Treatment of vitiligo is based on the clinical subtype, extent and location of the lesions, as well as the patient's age and preferences. Available therapeutic options include topical approaches, phototherapy, systemic therapy and surgical techniques, each with their own advantages and limitations.13

Topical therapies, involving the use of topical corticosteroids, calcineurin inhibitors and vitamin D analogs, aim to decrease local inflammation and stimulate cutaneous repigmentation. However, their efficacy can be variable and complete repigmentation may not be achieved in all cases.14

Phototherapy is another widely used treatment option for vitiligo, which involves exposing the skin to ultraviolet A (UVA) or ultraviolet B (UVB) radiation. Phototherapy can stimulate melanin production and promote repigmentation in some affected areas. However, it requires close monitoring and may involve prolonged and frequent sessions, as well as side effects such as skin irritation and premature skin aging.15

In certain cases of vitiligo, especially those with a segmental pattern, systemic therapy may be considered, including the use of oral corticosteroids or immunomodulatory agents. However, these therapies may carry adverse effects and should be carefully evaluated in each patient.15

In situations where conservative treatment has not been successful or is not feasible, surgical approaches such as skin transplantation, melanocyte grafting and epidermal cell micrografting can be considered. These surgical techniques seek to restore pigmentation to affected areas by transferring melanin-producing cells from donor areas to depigmented regions.15

It is important to keep in mind that the success of vitiligo treatment may vary from patient to patient and, in some cases, complete repigmentation may not be achieved. In addition, response to treatment can be slow and requires patience and perseverance on the part of both the patient and the physician.16

In summary, the treatment of vitiligo is a multifaceted approach that seeks to repigment affected areas, improve aesthetic appearance and address the associated psychosocial consequences. From topical therapies and phototherapy to systemic and surgical approaches, the goal is to provide comprehensive and personalized care to improve the quality of life of patients affected by this complex dermatologic disease.16

CONCLUSIONS

Vitiligo is a complex and enigmatic dermatologic disease of cutaneous depigmentation, whose etiology and pathogenesis continue to be the subject of intense research. Although its clinical presentation is characteristic, with the appearance of well-demarcated, depigmented macules on the skin, its clinical course can be highly variable, presenting challenges in its diagnosis and management.

The epidemiology of vitiligo reveals a heterogeneous geographical distribution and a variable prevalence according to regions, ethnic groups and demographic characteristics. Its psychosocial impact should not be underestimated, since depigmented macules can generate significant emotional consequences, affecting the quality of life of patients and leading to problems of self-esteem, anxiety and depression.

Despite advances in the understanding of its pathogenesis, vitiligo remains a chronic disease with no definitive cure. Although various therapeutic options have been developed, ranging from topical treatments and phototherapy to systemic and surgical approaches, the response to treatment can be variable and, in some cases, complete repigmentation may not be achieved.

Accurate diagnosis of vitiligo is essential for proper management and to rule out other skin depigmenting conditions. Health care professionals should use a detailed clinical evaluation, supported by the patient's medical history and, if necessary, by complementary tests.

It is essential to recognize the importance of a multidisciplinary approach in the treatment of vitiligo, involving dermatologists, autoimmune disease specialists and

mental health professionals to provide comprehensive and personalized care to affected patients.

Vitiligo continues to represent a therapeutic challenge and an evolving area of medical research. The future development of more specific and effective therapeutic approaches will depend on a better understanding of its pathogenesis, as well as collaboration and innovation in the field of dermatologic medicine.

Vitiligo is an enigmatic dermatological entity that demands comprehensive medical care, considering its various clinical, epidemiological and emotional facets. Although unknowns persist regarding its etiology and treatment, the commitment to research and personalized patient care will continue to be essential to improve its management and quality of life.

REFERENCES

I. Iannella G, Greco A, Didona D, Didona B, Granata G, Manno A, Pasquariello B, Magliulo G. Vitiligo: pathogenesis, clinical variants and treatment approaches. Autoimmunity Reviews. 2016 04;15(4):335-343. https://doi.org/10.1016/j.autrev.2015.12.006

II. Xie, H. et al. Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity? J Dermatol Sci. 2015; https://doi.org/10.1016/j.jdermsci.2015.09.003.

III. Speeckaert, R. et al. Vitiligo: An Update on Pathophysiology and Treatment Options. Am J Clin Dermatol. 2017; 18: 733-744. https://doi.org/10.1007/s40257-017-0298-5

IV. Rashighi, M. et al. Vitiligo pathogenesis and emerging treatments. Dermatol Clin. 2017; 35 (2): 257-265. https://doi.org/10.1016/j.det.2016.11.014

V. Mole, M. and Coringrato, M. Update on vitiligo. Dermatología Argentina. 2019; 25 (2): 50-57. Available: http://www.dermatolarg.org.ar/index.php/dermatolarg/article/viewArticle/1874

VI. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A comprehensive overview. Journal of the American Academy of Dermatology. 2011 09;65(3):473-491. https://doi.org/10.1016/j.jaad.2010.11.061

VII. Rodrigues, M. et al. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017; 77:1-13. http://dx.doi.org/10.1016/j.jaad.2016.10.048

VIII. Picardo M, Dell'Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D, Taieb A. Vitiligo. Nature Reviews DiseasePrimers. 2015 06 04;1(1). https://doi.org/10.1038/nrdp.2015.11.

IX. Boniface, K. et al. Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy. Clinic Rev Allerg Immunol. (2018); 54:52-67. https://doi.org/10.1007/s12016-017-8622-7

X. Goh B, Pandya AG. Presentations, Signs of Activity, and Differential Diagnosis of Vitiligo. Dermatologic Clinics. 2017 04;35(2):135-144. https://doi.org/10.1016/j.det.2016.11.004

XI. Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. International Journal of Dermatology. 2018 05 28;57(10):1157-1164. https://doi.org/10.1111/ijd.14055

XII. Blanca Lucina Campos-Cabrera, Juan Carlos Juárez-Echenique, Marimar Saez-de Ocariz, Luz Orozco-Covarrubias. Association between vitiligo and ophthalmologic alterations. Dermatol Rev Mex. 2019; 63 (3): 268-277. Available at:https://www.medigraphic.com/pdfs/derrevmex/rmd-2019/rmd193d.pdf

XIII. Elbuluk N, Ezzedine K. Quality of Life, Burden of Disease, Co-morbidities, and Systemic Effects in Vitiligo Patients. Dermatologic Clinics. 2017 04;35(2):117-128. https://doi.org/10.1016/j.det.2016.11.002

XIV. Passeron T. Medical and Maintenance Treatments for Vitiligo. Dermatologic Clinics. 2017 04;35(2):163-170. https://doi.org/10.1016/j.det.2016.11.007

XV. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. The Lancet. 2015 07;386(9988):74-84. https://doi.org/10.1016/s0140-6736(14)60763-7

XVI. Hönigsmann, H. and Schwarz, H. Ultraviolet light treatment, Physical treatment modalities. 2019; 2325-2341